Novartis Pharm Drug Patent Portfolio
Novartis Pharm owns 2 orange book drugs protected by 16 US patents Given below is the list of Novartis Pharm's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10596178 | Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide | 22 Jul, 2035 | Active |
| US7767675 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | 19 Nov, 2032 | Active |
| US8420645 | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | 05 Jun, 2031 | Active |
| US8901123 | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | 20 May, 2029 | Active |
| US12084449 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | 19 Nov, 2027 | Active |
| US8461330 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | 19 Nov, 2027 | Active |
| US8617598 | Pharmaceutical compositions comprising colloidal silicon dioxide | 27 Mar, 2023 | Expired |
| US8617598 | Pharmaceutical compositions comprising colloidal silicon dioxide | 27 Sep, 2022 | Expired |
| US8778962 | Treatment of solid tumors with rapamycin derivatives | 18 Aug, 2022 | Expired |
| US8778962 | Treatment of solid tumors with rapamycin derivatives | 18 Feb, 2022 | Expired |
| US7297703 | Macrolides | 06 Jun, 2020 | Expired |
| US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants | 09 Mar, 2020 | Expired |
| US7297703 | Macrolides | 06 Dec, 2019 | Expired |
| US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants | 09 Sep, 2019 | Expired |
| US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates | 12 Jan, 2017 | Expired |
| US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates | 12 Jul, 2016 | Expired |
Latest Legal Activities on Novartis Pharm's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Novartis Pharm.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Election Required | 18 Apr, 2024 | US7767675 |
| Notice of Final Determination -Election Required | 18 Apr, 2024 | US8420645 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 08 Dec, 2023 | US8420645 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 08 Dec, 2023 | US7767675 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Nov, 2023 | US8901123 |
|
Email Notification
Critical
| 20 Nov, 2023 | US8461330 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Nov, 2023 | US8461330 |
|
Email Notification
Critical
| 20 Nov, 2023 | US8901123 |
|
Email Notification
Critical
| 19 Sep, 2023 | US7767675 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 19 Sep, 2023 | US7767675 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 19 Sep, 2023 | US8420645 |
|
Email Notification
Critical
| 19 Sep, 2023 | US8420645 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 06 Sep, 2023 | US10596178 |
| Requirement for information sent under 37 CFR 1.750 | 29 Aug, 2023 | US8420645 |
| Requirement for information sent under 37 CFR 1.750 | 29 Aug, 2023 | US7767675 |
Novartis Pharm's Drug Patent Litigations
Novartis Pharm's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2015, against patent number US7297703. The petitioner Par Pharmaceutical, Inc., challenged the validity of this patent, with Novartis AG as the respondent. Click below to track the latest information on how companies are challenging Novartis Pharm's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5665772 | October, 2015 |
FWD Entered
(11 Jan, 2018)
| Novartis AG | Par Pharmaceutical, Inc. |
| US5665772 | May, 2016 |
FWD Entered
(27 Oct, 2016)
| Novartis AG | BRECKENRIDGE PHARMACEUTICAL, INC. |
| US5665772 | May, 2016 |
Terminated-Denied
(27 Oct, 2016)
| Novartis AG | Par Pharmaceutical, Inc. |
| US5665772 | May, 2016 |
FWD Entered
(27 Oct, 2016)
| Novartis AG | Roxane Laboratories, Inc. |
| US5665772 | May, 2016 |
Terminated-Denied
(27 Oct, 2016)
| Novartis AG | Breckenridge Pharmaceutical, Inc. |
| US7297703 | October, 2015 |
Terminated-Denied
(01 Apr, 2016)
| Novartis AG | Par Pharmaceutical, Inc. |
Novartis Pharm Drug Patents' Oppositions Filed in EPO
Novartis Pharm drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 18, 2016, by Teva Pharmaceutical Industries Ltd. This opposition was filed on patent number EP10174983A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP18155722A | Jan, 2023 | Generics [UK] Limited | Granted and Under Opposition |
| EP18155722A | Jan, 2023 | Ethypharm | Granted and Under Opposition |
| EP18155722A | Jan, 2023 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP15744702A | Sep, 2021 | D Young & Co LLP | Granted and Under Opposition |
| EP18155724A | Jun, 2020 | ARROW GENERIQUES | Granted and Under Opposition |
| EP18155724A | May, 2020 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP18155724A | May, 2020 | Zentiva k.s. | Granted and Under Opposition |
| EP18155724A | May, 2020 | Generics [UK] Ltd | Granted and Under Opposition |
| EP18155724A | Apr, 2020 | PUREN Pharma GmbH & Co. KG | Granted and Under Opposition |
| EP18155644A | Feb, 2020 | ARROW GENERIQUES | Granted and Under Opposition |
| EP18155644A | Feb, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP18155644A | Feb, 2020 | Generics [UK] Limited | Granted and Under Opposition |
| EP18155724A | Feb, 2020 | Ethypharm | Granted and Under Opposition |
| EP18155644A | Jan, 2020 | Dr. Reddy's Laboratories Limited | Granted and Under Opposition |
| EP18155724A | Sep, 2019 | BIOGARAN | Granted and Under Opposition |
| EP18155644A | Sep, 2019 | Zentiva Pharma GmbH | Granted and Under Opposition |
| EP16186041A | Sep, 2019 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP16186041A | Sep, 2019 | Generics [UK] Ltd | Granted and Under Opposition |
| EP16186041A | Sep, 2019 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP16186041A | Sep, 2019 | Zentiva k.s. | Granted and Under Opposition |
| EP16186041A | Aug, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP16186041A | Aug, 2019 | Synthon B.V. | Granted and Under Opposition |
| EP18155724A | Aug, 2019 | Dr. Reddy's Laboratories / Betapharm Arzneimittel GmbH | Granted and Under Opposition |
| EP18155724A | Aug, 2019 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP18155724A | Aug, 2019 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP18155644A | Jul, 2019 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP10174983A | Jul, 2019 | Zentiva France | Revoked |
| EP18155644A | Jul, 2019 | Ethypharm | Granted and Under Opposition |
| EP18155644A | Jul, 2019 | BIOGARAN | Granted and Under Opposition |
| EP16186041A | Jun, 2019 | Ethypharm | Granted and Under Opposition |
| EP18155644A | May, 2019 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP09751439A | Apr, 2018 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP14164259A | Mar, 2018 | Generics (UK) Ltd | Revoked |
| EP14164565A | Dec, 2017 | Ethypharm | Revoked |
| EP14164565A | Dec, 2017 | Generics (U.K.) Limited | Revoked |
| EP10174985A | Apr, 2017 | STADA Arzneimittel AG | Revoked |
| EP10174985A | Apr, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP10174985A | Apr, 2017 | Generics [UK] Ltd | Revoked |
| EP10174985A | Apr, 2017 | Intas Pharmaceuticals Ltd. | Revoked |
| EP10174985A | Apr, 2017 | Wittkopp, Alexander | Revoked |
| EP10174985A | Apr, 2017 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP10174985A | Apr, 2017 | KRKA, d.d., Novo mesto | Revoked |
| EP10174985A | Apr, 2017 | Synthon Biopharmaceuticals B.V. | Revoked |
| EP10174983A | Feb, 2016 | Synthon B.V. | Revoked |
| EP10174983A | Feb, 2016 | Wittkopp, Alexander | Revoked |
| EP10174983A | Feb, 2016 | Actavis PTC ehf | Revoked |
| EP10174983A | Feb, 2016 | Intas Pharmaceuticals Ltd. | Revoked |
| EP10174983A | Feb, 2016 | STADA Arzneimittel AG | Revoked |
| EP10174983A | Feb, 2016 | Ethypharm | Revoked |
| EP10174983A | Feb, 2016 | Generics [UK] Limited | Revoked |
| EP10174983A | Feb, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
Novartis Pharm's Family Patents
Novartis Pharm drugs have patent protection in a total of 51 countries. It's US patent count contributes only to 10.5% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Novartis Pharm Drug List
Given below is the complete list of Novartis Pharm's drugs and the patents protecting them.
1. Afinitor Disperz
Afinitor Disperz is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8617598
(Pediatric)
| Pharmaceutical compositions comprising colloidal silicon dioxide |
27 Mar, 2023
(1 year, 6 months ago)
| Expired |
| US8617598 | Pharmaceutical compositions comprising colloidal silicon dioxide |
27 Sep, 2022
(2 years ago)
| Expired |
| US8778962
(Pediatric)
| Treatment of solid tumors with rapamycin derivatives |
18 Aug, 2022
(2 years ago)
| Expired |
| US8778962 | Treatment of solid tumors with rapamycin derivatives |
18 Feb, 2022
(2 years ago)
| Expired |
| US7297703
(Pediatric)
| Macrolides |
06 Jun, 2020
(4 years ago)
| Expired |
| US5665772
(Pediatric)
| O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
09 Mar, 2020
(4 years ago)
| Expired |
| US7297703 | Macrolides |
06 Dec, 2019
(4 years ago)
| Expired |
| US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
09 Sep, 2019
(5 years ago)
| Expired |
| US6004973
(Pediatric)
| Pharmaceutical compositions comprising rafamycin coprecipitates |
12 Jan, 2017
(7 years ago)
| Expired |
| US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates |
12 Jul, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Afinitor Disperz's drug page
2. Tabrecta
Tabrecta is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10596178 | Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide |
22 Jul, 2035
(10 years from now)
| Active |
| US7767675 | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
19 Nov, 2032
(8 years from now)
| Active |
| US8420645 | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
05 Jun, 2031
(6 years from now)
| Active |
| US8901123 | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
20 May, 2029
(4 years from now)
| Active |
| US12084449 | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
19 Nov, 2027
(3 years from now)
| Active |
| US8461330 | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
19 Nov, 2027
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tabrecta's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List